Amylin Levels in Migraine Patients on New Treatment
Part of Brain & nervous system clinical trials.
This study looks at how a substance called amylin changes in people with migraines when they start taking a new class of migraine medicines (anti-CGRP antibodies). It aims to help understand why these treatments work and might lead to better options for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high frequency episodic migraine or chronic migraine.
- You have been prescribed an anti-CGRP or anti-CGRP receptor antibody treatment (like Aimovig, Emgality, or Ajovy) but haven't started it yet.
- You are 18 years old or older.
- If you are a healthy volunteer, you must not have any history of migraines or other headaches and not use daily painkillers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at the chemical changes in the blood of people with migraine. It aims to better understand the disease and may help find new treatments. You may qualify if you have episodic or chronic migraine and have not tried CGRP-targeting drugs.
This study tests whether a natural substance called amylin can trigger a migraine attack in people who get migraine without aura. If you have 1 to 5 migraine days a month and are otherwise healthy, you may be able to help researchers understand what causes migraines.
This study tests a new treatment (anti-CGRP antibodies) to prevent migraine attacks from becoming chronic. It looks at whether we can predict who will respond best, aiming to find better long-term control for people with frequent or chronic migraine.
This study looks for new biological markers in people whose migraines don't respond to standard treatments. It aims to better understand why some migraines are hard to treat and may help guide future therapies.
This study is building a database to learn more about migraine drugs. It may help researchers find better treatments for people with episodic or chronic migraine.
This study tests a CGRP-blocking antibody to see how it affects migraine symptoms and the body’s automatic (involuntary) nerve functions. It may help people with migraine who have already tried several preventive medicines.
Hear when a new High Frequency Episodic Migraine and Chronic Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.